Dulaglutide vs Epigen
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →Epigen
Epigen is a member of the epidermal growth factor (EGF) family. It plays roles in skin regeneration and has been studied for wound healing and anti-aging applications.
Full details →Side-by-Side Comparison
| Aspect | Dulaglutide | Epigen |
|---|---|---|
| Mechanism | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. | Binds to and activates the EGF receptor (EGFR), promoting cell proliferation, migration, and differentiation. Involved in skin homeostasis and repair processes. |
| Typical Dosage | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. | Topical: Typically used at low concentrations (ppm to low %) in cosmetic formulations. Research applications vary. |
| Administration | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. | Primarily topical application for skincare. Research may use other routes for systemic effects. |
| Side Effects | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. | Topical use generally well-tolerated. Theoretical concerns about promoting cell proliferation. |
| Best For |